Medtronic to Acquire EPIX Therapeutics for its Cardiovascular Technologies

 Medtronic to Acquire EPIX Therapeutics for its Cardiovascular Technologies

Medtronic to Acquire EPIX Therapeutics for its Cardiovascular Technologies

Shots:

  • Medtronic acquires EPIX Therapeutics, in all-stock transaction with its DiamondTemp Ablation system & Arctic Front Advance Cryoablation System. The acquisition is expected to close in Q4’19 i.e 26 Jan to 26 April, 2019
  • The focus of the acquisition is to expand and strengthen Medtronic’s cardiology platform offering therapies for patients with cardiac arrhythmias
  • DiamondTemp is a real-time, temperature-controlled system, providing electrogram using radiofrequency energy for atrial fibrillation (AF) and has received EU’s CE Mark Clearance in 2017. Arctic Front Advance is a system involved in the isolation of pulmonary veins using Cyro energy approved by the US

Click here to read full press release/ article | Ref: Medtronic | Image: The Commercial Appeal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post